David A. Siegel Intellia Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 659,317 shares of NTLA stock, worth $14.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
659,317
Previous 464,017
42.09%
Holding current value
$14.8 Million
Previous $14.1 Million
28.2%
% of portfolio
0.04%
Previous 0.03%
Shares
22 transactions
Others Institutions Holding NTLA
# of Institutions
313Shares Held
89.3MCall Options Held
686KPut Options Held
599K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11MShares$246 Million2.16% of portfolio
-
Black Rock Inc. New York, NY9.11MShares$204 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$204 Million0.01% of portfolio
-
State Street Corp Boston, MA4.6MShares$103 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.21MShares$94.2 Million3.83% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.7B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...